Breaking News
Guidelines for the Management of Transfusion Dependent Thalassaemia (4th Edition – 2021)
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
Global Thalassaemia Review (2021)
TIF Is Actively Participating In The 26th EHA Annual Congress
TIF Proudly Supports World Blood Donor Day 2021
Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies
TIF e-Academy: Reimagining Thalassaemia and Sickle Cell Disease Education
US STUDY: COVID-19 Does Not Pose A Threat To Blood And Transfusion Safety
Chinese Sinovac COVID-19 Vaccine Approved By World Health Organization
TIF Position Statement: Addressing Blood Supply Issues Linked To COVID-19 Vaccination Deferral Times
English
Ελληνικά
Français
Deutsch
Italiano
العربية
Menu
Home
Who we are
TIF History
Vision & Mission
Pillars of Work
Board of Directors
Staff Members
TIF Members
Collaborations
Transparency
Awards & Honours
What we do
Education
Country work
Projects
Haemoglobin Disorders
Thalassaemia
Sickle Cell Disease
Clinical Trial Updates
Positions & Policies
Policy Framework
Position Papers
Official Statements
Publications
TIF Publications
Scientific Literature
Additional Resources
Media Centre
News
Newsletters
Events
Videos
Contact us
Search for
RSS
Instagram
YouTube
Twitter
Facebook
Home
/
What we do
What we do
Back to top button
Close
Search for
Cookies
This site uses cookies.
Find out more
Okay, thanks
